other barriers associated with xenotransplantation must be overcome with various strategies for the genetic modification of pigs. In this review, we summarize the outcomes of genetically modified and cloned pigs achieved by Chinese scientists to resolve the above-mentioned problems in xenotransplantation. It is now possible to knockout several porcine genes associated with the expression of sugar residues, antigens for (naturally) existing antibodies in humans, including GGTA1, CMAH, and β4GalNT2, and thereby preventing the antigen-antibody response. Moreover, insertion of human complement-and coagulation-regulatory transgenes, such as CD46, CD55, CD59, and hTBM, can further overcome effects of the humoral immune response and coagulation dysfunction, while expression of regulatory factors of immune responses can inhibit the adaptive immune rejection. Furthermore, transgenic strategies have been developed by Chinese scientists to reduce the potential risk of infections by endogenous porcine retroviruses (PERVs). Breeding of multi-gene lowimmunogenicity pigs in China is also presented in this review. Lastly, we will briefly mention the preclinical studies on pig-to-non-human primate xenotransplantation conducted in several centers in China.
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| INTRODUC TI ON
Organ transplantation is the most effective means of treating endstage organ failure, but the serious shortage of donor organs has become a main obstacle to the expansion of organ transplantation.
According to the database of the China Organ Transplantation
Volunteer Network, over 300 000 patients are on the waiting list, but only about 16 000 will undergo transplantation every year (http:// union.china.com.cn/jdtp/txt/2018-08/02/content_40445532. html). In 2015, the Chinese human organ transplant ordinances halted transplantations using organs from executed convicts, which has exacerbated the organ resource shortage. To overcome these problems, multi-layered genetic modification is required. In other words, the complex mechanisms of immune incompatibility between the donor and the recipient must be countered by multiple gene modifications.
| HAR AND AHXR
After a wild-type (ie, genetically unmodified) pig organ is transplanted into a patient or into a non-human primate, the immune response is dramatically rapid, with HAR occurring generally within minutes, 10 To circumvent HAR, Lai and his team have successfully generated pigs with heterozygous knockout of GGTA1 (GTKO) using homologous recombination (HR) in 2002. 11 In the same year, Dai et al also reported the single allele disruption in the GGTA1 gene. 12 The production of GGTA1 knockout swine was a major victory in the search for human organ replacements. Our team produced one GGTA1 allelic knockout fetus via effectively constructing the promoter-less vector targeting the exon 4 locus of GGTA1 gene, 13 and for further study, we established a highly efficient method for enriching TALENtargeted biallelic KO cells to create genetically modified pigs with expected genotypes and evaluated the fertility and heredity of the TALEN-modified pigs.
14 Kefeng Dou is the leading scientist in China to perform pig-to-nonhuman primate liver transplantation, and his team used organs from GTKO minipigs generated by our laboratory to complete 10 cases of pig-to-Tibetan macaque auxiliary liver xenotransplantation. As expected, Tibetan macaques receiving liver xenografts did not exhibit severe coagulopathy or immune rejection and the pig liver functioned well for 14 days, which created a world record in xenotransplantation at that time.
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GGTA1-KO xenografts are, however, still subject to AHXR, attesting to endothelial activation probably by induced antibodies to non-Gal antigens expressed on pig tissues. 16 The currently identified non-Gal antigens include sialic acid N-glycolylneuraminic acid (NeuGc) synthesized under the influence of the CMAH (cytidine monophospho-N-acetylneuraminic acid hydroxylase) gene, 17 and a carbohydrate antigen (SDa) produced under the influence of the porcine β1,4 N-acetylgalactosaminyltransferase-2 (β4GalNT2) gene. 18, 19 On the basis of the GGTA1 knockout, our group successfully produced GGTA1/CMAH, GGTA1/βGalNT2-knockout, low-immunogenic Bama minipigs via knockout of the NeuGc and β4GalNT2
antigens that caused post-αGal-related rejection. 20 26 and CD59
(membrane inhibitor of reactive lysis, MIRL). 27 The incidence of antibody-mediated rejection was further reduced with xenografts from GTKO pigs that also expressed hCRPs (GTKO/hCRP pigs). 28 Inhibition of complement activation by the expression of hCD46 on porcine islets was effective in blocking antibody-mediated rejection in islet xenotransplantation in diabetic cynomolgus monkeys, maintaining normoglycemia for more than a year. 29 Our team reconstructed the engineered hCD46 minigene and generated transgenic and hCD59 on top of the GTKO genetic background prominently enhanced the protective effect against human serum-mediated cytolysis when compared with the GTKO-alone condition. 6 Taken together, GTKO pig added one or two hCRPs should be a more suitable donor for xenotransplantation.
| COAG UL ATION DYS FUN C TION
Porcine endothelial cell activation processes are accompanied by vascular prothrombotic and inflammatory changes, which cause TMA and DIC that are distinctive characteristics of xenograft rejection, regardless of the level of complement activation. processes. 33 Our group highlighted the expression of anti-coagulation factor hTBM in transgenic pig vascular endothelium, which overcomes the clotting disorders caused by molecular incompatibilities. 34 EPCR plays a vital role in anticoagulant, anti-inflammatory, and cytoprotective signaling by binding protein C and presenting it to the TBM/thrombin complex for activation, and therefore prolong the survival time of donor organs in the recipients. 35 Transgenic hEPCR minipigs have been successfully produced in our laboratory, and the hEPCR gene has high expression in the main organs and tissues of cloned pigs that hence have become a good donor for heterologous kidney transplantation studies (unpublished data). The recipient TF was not inhibited efficiently owing to species incompatibility between human TF and pig TFPI. 36 We developed immortalized pig bone marrow mesenchymal cells (BMSCs) transfected with human TFPI, further demonstrating that inhibiting the activation of recipient TF may provide a meaningful method for controlling coagulation dysregulation. 37 
| CELLUL AR RE JEC TION
In addition to the humoral immune response and coagulopathy, the next obstacle for pig-to-non-human primate xenotransplantation is cellular rejection which is mainly due to rejection by non-human primate immune cells, including natural killer (NK) cells, monocytes/ macrophage, and T lymphocytes. 38 Inhibition of the T cell-mediated immune response by expressing regulatory factors of adaptive immune responses in the pig genome further reduces rejection following xenotransplantation using GTKO pig organs. 38 Cytotoxic T lymphocyte-associated antigen (CTLA4) is a co-stimulatory blockade agent that inhibits T-cell activity in islet cells of transgenic pigs and may be useful in prolonging graft rejection. 39, 40 Based on the previous production experience of GTKO pigs, our group successfully screened for a genetically stable line of LEA29Y transgenic pigs (LEA29Y being a CTLA4-Ig derivative), which can serve as a reliable donor for the study of islet xenotransplantation. 40 Moreover, the xenograft would also be damaged by host macrophages after binding the receptor because the signal regulatory protein α (SIRPα) receptors on macrophages cannot specifically recognize the cell-surface integrin-associated protein (CD47) on xenografted cells which has been shown to inhibit phagocytosis by non-human primate macrophages. 41 Hawley et al reported the generation of hCD47-transgenic miniature swine on a GGTA1-null background and demonstrated the high-level ability to achieve mixed chimerism between xenografted hematopoietic cells and recipient cells. 42 Our group has also successfully generated GTKO Bama minipigs with hCD47 genes which avoid HAR and weaken the phagocytosis by host macrophages for various xenografted organs. 43 To further reduce immunogenicity, an alternative strategy is the production of pigs in which a mutant CIITA (MHC class II transactivator) gene has been introduced, resulting in inhibition of transcription and expression of swine leukocyte antigen class II in the vascular endothelium. 7 Dai et al reported that human dominant-negative CIITA-transgenic pigs on a wild-type (WT) background are potential sources of organs/tissues/cells for xenotransplantation. 44 
| PERVS , A P OTENTIAL RIS K IN XENOTR ANS PL ANTATION
To a great extent, the pathobiologic barriers in xenotransplantation have been defined. Research on xenograft rejection has advanced through the increasing availability of genetically engineered pigs and novel immunosuppressive agents. 45 However, xenozoonosis is a concern due to the potential transmission of infectious agents, in particular porcine endogenous retroviruses (PERVs), from the pig transplant to the human recipient. PERVs are integrated in the genome of every pig cell, and thus will inevitably be transplanted with the organ or cells. 8 The multiplexing capability of the CRISPR/Cas9 system seemed to be an ideal approach to inactivate multiple copies of PERV sequences in somatic cells, and the cells could be used as a donor for SCNT to generate PERV-free pigs. 46 Luhan Yang and her team achieved the eradication of all 62 PERV copies in a porcine kidney epithelial cell line (PK15) and demonstrated a significant reduction in in vitro transmission of PERVs to human cells using engineered cells. 47 Our group has found that mutant efficiency of the PERV pol gene is about 30% (unpublished data). Furthermore, Yang et al produced PERV-inactivated live pigs using PERV-inactivated primary porcine cell lines. 46 Although it has been confirmed that PERVs can be transmitted from pig to human cells and horizontally transmitted among human cells in vitro, it is still unclear whether PERVs infect humansin vivo. 46 There have been no reports of PERV causing disease in humans, and numerous studies have indicated that cells from transgenic pigs do not release human-tropic PERV. 48 However, clinical data of xenotransplantation are too limited to unequivocally support the conclusion that there is noin vivo PERV transmission. 49 Some researchers have debated whether it makes sense to knockout all copies of PERVs without confirming the risk of infection. 49, 50 Taken together, PERV inactivation is useful to prevent potential cross-species viral transmission, and the successful production of PERV-inactivated animals may address an important barrier to the feasibility of clinical trials of xenotransplantation.
| MULTI -G ENE LOW-IMMUNOG ENICIT Y PI G B REED ING
There are various immunological barriers between pig tissues/organs and primates, including HAR mediated by naturally existing xenoreactive antibodies, AHXR mediated mainly by (elicited) antibodies to non-Gal antigens and complement, coagulation disorders caused by endothelial activation and molecular incompatibilities of coagulation factors, and rejection mediated by various immune cells. 7 Our group has carried out a variety of transgenic modifications in the pig genome to knockout or insert human genes that inhibit the corresponding rejection reaction, so as to gradually overcome the above immunological obstacles. We have bred 7 kinds of genetically modified pig breeds using Bama and Wuzhishan minipigs, which have knocked out one or more antigens, such as α-1,3-Gal, NeuGc, and β4GalNT2, and also have inserted transgenes CD46, CD47, TBM, or LEA29Y to regulate immune rejection.
Stable inheritance and normal reproductive capacity are continuously observed in GTKO minipigs and GGTA1/CMAH knockout minipigs. 20, 51 Currently, GTKO pigs have been bred to the fifth generation in our laboratory. Besides, our group has continuously traced the inheritance and expression of two-generation LEA29Y-transgenic pigs and obtained islet-specific expression of LEA29Y transgenic pigs for islet xenografting. 40 There are more than 100 pigs of genetically modified pig strains in our facility, including, among others, boars, sows, pregnant sows, young pigs, weaned piglets: These are resources of various organs for xenotransplantation experiments. In addition,
we have combined genetic editing and cross-breeding techniques to produce a variety of multi-gene low-immunogenic pigs.
For instance, the GTKO/hCD46/hTBM triple-transgenic pigs were generated rapidly by one step of SCNT, with pig fibroblast cotransfected with TALEN mRNA targeting GGTA1 and two other expression vectors as nuclear donors. This approach can reduce multiple transgenic pig breeding cycles and achieve a high expression level of hCD46 and hTBM (unpublished data). An American group of scientists transplanted a porcine heart from GTKO/ hCD46/hTBM triple-gene-knockout (TKO) pigs to baboon recipients, leading to long-term cardiac xenograft survival beyond 900 days.
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GTKO/hCD46/LEA29Y and GTKO/β4GalNT2KO/hCD46/ hCD47 pig have been developed by mating, which provide an ideal donor for islet or kidney transplantation to non-human primates.
GGTA1/CMAH/β4GalNT2 TKO pigs also are bred by hybrid breeding of GGTA1/CMAH knockout pigs and GGTA1/β4GalNT2 knockout pigs. 
| CON CLUS I ON S AND PER S PEC TIVE S
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